EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • April 9th, 2015 • Interleukin Genetics Inc • In vitro & in vivo diagnostic substances • Massachusetts
This Employment Agreement (the “Agreement”), made and entered into this 6th day of April, 2015 (the “Effective Date”), by and between Interleukin Genetics, Inc, a Delaware corporation (“Company”), and Mark Carbeau (“Executive”).
THIRD AMENDMENT TO THE COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • April 9th, 2015 • Interleukin Genetics Inc • In vitro & in vivo diagnostic substances
This Third Amendment (the “Amendment”) to the Common Stock Purchase Agreement, dated May 17, 2013 (as on March 31, 2014 and May 30, 2014), by and among Interleukin Genetics, Inc., a Delaware corporation (the “Company”), and the Purchasers identified on Schedule I thereto (the “Purchase Agreement”), is made as of April 6, 2015, by and among the Company and the Purchasers set forth on the signature page hereto. Capitalized terms used herein but not defined shall have the meanings ascribed to such terms in the Purchase Agreement.
FIRST AMENDMENT TO THE SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 9th, 2015 • Interleukin Genetics Inc • In vitro & in vivo diagnostic substances
This First Amendment (the “Amendment”) to the Securities Purchase Agreement, dated December 23, 2014, by and among Interleukin Genetics, Inc., a Delaware corporation (the “Company”), and the Purchasers identified on Schedule I thereto (the “Purchase Agreement”), is made as of April 6, 2015, by and among the Company, the Purchasers set forth on the signature page hereto and Pyxis Innovations Inc. (“Pyxis”). Capitalized terms used herein but not defined shall have the meanings ascribed to such terms in the Purchase Agreement.
